clinical trial · NCT06743035
Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly
iOMEDICO AG·—·recruiting·n = 200
Polycythemia Vera
brief summary
The primary objective of this non interventional study is to evaluate symptom burden in adult patients with PV without symptomatic splenomegaly during treatment with ropeginterferon alfa-2b in a real-world setting. Further patient-relevant endpoints include effectiveness including complete hematologic response (CHR), event-free survival (EFS), safety and tolerability, treatment reality including dosing details as well as factors affecting treatment decision making.
started
Dec 3, 2024
primary completion
Jul 1, 2029
completion
Jul 1, 2029
last updated
Jan 9, 2026
official title
Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly: A Prospective, Longitudinal, Multicenter, Observational Study in Germany
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol